Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 6/20 | 0.39 |
| ▸ | JAK3 | P52333 | 6/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379341 | 0.85 | JAK1 (0.42) | JAK1JAK2JAK3TYK2PDE9A | |
| SCHEMBL14752117 | 0.85 | JAK1 (0.42) | JAK1JAK2JAK3TYK2PDE9A | |
| SCHEMBL2377922 | 0.83 | JAK1 (0.39) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2380450 | 0.83 | JAK1 (0.43) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2379723 | 0.82 | JAK1 (0.40) | JAK1JAK2JAK3TYK2PDE9A | |
| SCHEMBL14752027 | 0.81 | JAK1 (0.48) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL14747139 | 0.80 | JAK1 (0.50) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL14655969 | 0.80 | KDM2A (0.35) | KDM5CKDM2AKDM3A | |
| SCHEMBL2378534 | 0.79 | JAK1 (0.62) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2379582 | 0.79 | JAK1 (0.46) | JAK1JAK2JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | JAK1 6/4885JAK2 5/4885JAK3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.